[at Seeking Alpha] – Gilead Sciences ( GILD ), a biopharmaceutical research company, indeed has traits of a growth stock. Gilead Sciences reported $9.7 billion in sales for the 2012 fiscal year. In . . . → Read More: Gilead Sciences Inc. (NASDAQ:GILD) – New Hepatitis C Drug Success Should Drive Gilead Sciences In 2014 Similar posts: AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial The Procter & Gamble Company (NYSE:PG) – Companies’ most neglected resource for success Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review